Published date: Mar 31 2023

Journal Title: Sudan Journal of Medical Sciences

Issue title: Sudan JMS: Volume 18 (2023), Issue No. 1

Pages: 117–120

DOI: 10.18502/sjms.v18i1.12872

Mohadeseh NematiDepartment of Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran

Fahima Danesh PouyaDepartment of Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran

Elmira Roshani AslDepartment of Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran

Yousef Rasmirasmiy@umsu.ac.irDepartment of Biochemistry, School of Medicine, Urmia University of Medical Sciences, Urmia, Iran

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new coronavirus named by the International Committee on Taxonomy of Viruses. COVID-19 patients have high mortality due to respiratory failure from acute respiratory distress syndrome (ARDS) induced by SARS-CoV-2. The abnormal activation of P21-activated kinase (PAK1, RAC/CDC42-activated kinase 1) is reported in COVID-19. The PAK1 induces nuclear factor kappa B (NF-κB) activation as well as inflammatory pathways through its stimulation. BAY 11-7082 {(E) 3-[(4-methylphenyl)-sulfonyl]-2-propenenitrile is one of the therapies that inhibit inflammation via mentioned signaling pathway, therefore, we suggest that this drug can potentially be effective in treating COVID-19.

Keywords: BAY 11-7082, COVID-19, PAK1

[1] Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M.,…Cao, B. (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 395(10223), 497–506.

[2] Liu, Y., Gayle, A. A., Wilder-Smith, A., & Rocklöv, J. (2020). The reproductive number of COVID-19 is higher compared to SARS coronavirus. Journal of Travel Medicine, 27(2), taaa021.

[3] Ruan, Q., Yang, K., Wang, W., Jiang, L., & Song, J. (2020). Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Medicine, 46(5), 846–848.

[4] Maruta, H. (2014). Herbal therapeutics that block the oncogenic kinase PAK1: A practical approach towards PAK1‐dependent diseases and longevity. Phytotherapy Research, 28(5), 656–672.

[5] Maruta, H., & He, H. (2020). PAK1-blockers: Potential therapeutics against COVID-19. Medicine in Drug Discovery, 6, 100039.

[6] Dammann, K., Khare, V., & Gasche, C. (2014). Tracing PAKs from GI inflammation to cancer. Gut, 63(7), 1173–1184.

[7] Bowie, A., & O’Neill, L. A. (2000). Oxidative stress and nuclear factor-κB activation: A reassessment of the evidence in the light of recent discoveries. Biochemical Pharmacology, 59(1), 13–23.

[8] Tedgui, A., & Mallat, Z. (2001). Anti-inflammatory mechanisms in the vascular wall. Circulation Research, 88(9), 877–887.

[9] Pierce, J. W., Schoenleber, R., Jesmok, G., Best, J., Moore, S. A., Collins, T., & Gerritsen, M. E. (1997). Novel inhibitors of cytokine-induced IκBα phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. Journal of Biological Chemistry, 272(34), 21096–21103.

[10] Malladi, V., Puthenedam, M., Williams, P. H., & Balakrishnan, A. (2004). Enteropathogenic Escherichia coli outer membrane proteins induce iNOS by activation of NF-κB and MAP kinases. Inflammation, 28(6), 345–353.

[11] Xue, W., Meylan, E., Oliver, T. G., Feldser, D. M., Winslow, M. M., Bronson, R., & Jacks, T. (2011). Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma. Cancer Discovery, 1(3), 236–247.

[12] Strickson, S., Campbell, D. G., Emmerich, C. H., Knebel, A., Plater, L., Ritorto, M. S., Shpiro, N., & Cohen, P. (2013). The anti-inflammatory drug BAY 11-7082 suppresses the MyD88-dependent signalling network by targeting the ubiquitin system. Biochemical Journal, 451(3), 427–437.

[13] Juliana, C., Fernandes-Alnemri, T., Wu, J., Datta, P., Solorzano, L., Yu, J.-W., Meng, R., Quong, A. A., Latz, E., Scott, C. P., & Alnemri, E. S. (2010). Anti-inflammatory compounds parthenolide and Bay 11-7082 are direct inhibitors of the inflammasome. Journal of Biological Chemistry, 285(13), 9792–9802.

[14] Martinon, F., Mayor, A., & Tschopp, J. (2009). The inflammasomes: Guardians of the body. Annual Review of Immunology, 27, 229–265.

[15] Dinarello, C. A. (1998). Interleukin‐1β, Interleukin‐18, and the Interleukin‐1β converting enzyme. Annals of the New York Academy of Sciences, 856(1), 1–11.

[16] Dinarello, C. A. (2009). Immunological and inflammatory functions of the interleukin-1 family. Annual Review of Immunology, 27, 519–550.

[17] Hornung, V., Bauernfeind, F., Halle, A., Samstad, E. O., Kono, H., Rock, K. L., Fitzgerald, K. A., & Latz, E. (2008). Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization. Nature Immunology, 9(8), 847.